Aeterna Zentaris Announces Expiration of Remaining Series B Warrants
September 14 2016 - 8:30AM
Business Wire
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”)
today announced that the remaining 8,064 Series B Common Share
Purchase Warrants (the “Series B Warrants”) issued in connection
with the Company’s March 2015 financing expired on September 12,
2016 without being exercised. The Company had 9,939,863 Common
Shares issued and outstanding as of the close of business on
September 13, 2016.
David A. Dodd, President and Chief Executive Officer of the
Company, explained, “All Series B Warrants issued in connection
with our March 2015 financing have now been extinguished.
Therefore, there will be no further dilution of our shareholders as
a result of the Series B Warrants. I am pleased that we can report
that the repair of our capital structure is now complete. We are
looking forward to the impending completion of the pivotal, Phase
III trials for Macrilen™ and Zoptrex™ and to the submission of NDAs
for the products, if the results of the trials warrant doing
so.”
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel treatments in
oncology, endocrinology and women’s health. We are engaged in drug
development activities and in the promotion of products for others.
We are now conducting Phase 3 studies of two internally developed
compounds: Macrilen™ and Zoptrex™. The focus of our business
development efforts is the acquisition of licenses to products that
are relevant to our therapeutic areas of focus. We also intend to
license out certain commercial rights of internally developed
products to licensees in territories where such out-licensing would
enable us to ensure development, registration and launch of our
product candidates. Our goal is to become a growth-oriented
specialty biopharmaceutical company by pursuing successful
development and commercialization of our product portfolio,
achieving successful commercial presence and growth, while
consistently delivering value to our shareholders, employees and
the medical providers and patients who will benefit from our
products. For more information, visit www.aezsinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160914005365/en/
Aeterna Zentaris Inc.Philip A. Theodore, 843-900-3223Senior Vice
Presidentir@aezsinc.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024